Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo, hair loss is not universal on Mounjaro. Most people do not experience it. A proportion of patients on tirzepatide do notice increased shedding, particularly in the first few months of treatment, but this is linked to rapid weight loss rather than the medicine directly — and it is almost always temporary. As a prescription-only medicine, Mounjaro requires clinical assessment before it is prescribed; a qualified prescriber considers your full health picture, including factors that raise or lower the chance of side effects like this one. Understanding why it happens, who it tends to affect, and what to expect can take a lot of the worry out of it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The hair growth cycle has three phases: active growth (anagen), transition (catagen), and rest (telogen), after which hairs shed naturally. Physical stressors (major illness, surgery, childbirth, and rapid weight loss) can push a larger-than-usual proportion of follicles into the resting phase simultaneously. Two to four months later, those resting hairs shed in a cluster. This is called telogen effluvium.
Mounjaro itself is not directly listed as a cause of hair loss in the medicine's Summary of Product Characteristics. What tends to drive shedding is the speed and scale of weight reduction. In the SURMOUNT-1 trial, participants lost an average of around 20% of body weight over 72 weeks, a meaningful metabolic change that the body registers as a significant event. Some follicles respond accordingly.
The result is diffuse thinning rather than patchy loss, usually noticeable across the scalp rather than in one spot. It is the same mechanism that causes postpartum shedding, which is why clinicians sometimes reach for that analogy. The follicles themselves are unharmed. You can read more about how tirzepatide works at a clinical level on the tirzepatide overview page.
Not everyone who loses weight rapidly on Mounjaro sheds noticeably. Several factors make some patients more susceptible than others.
Protein intake matters enormously. Hair is almost entirely keratin, a protein, and when calorie intake drops sharply, the body deprioritises non-essential protein uses. If you are eating well below your usual intake and not actively protecting protein targets, follicles get less of what they need to stay in the growth phase. This is worth knowing before you start treatment, not after.
Iron, zinc, and ferritin levels also play a role. Pre-existing borderline deficiencies (common in women of reproductive age and not always caught on standard blood tests) can be unmasked by rapid weight loss. It is worth asking your prescriber whether baseline bloods make sense for you.
The rate of weight loss itself is a factor. Faster losses, particularly in the first few months when appetite suppression is pronounced, correlate with more noticeable shedding. Patients who titrate more slowly or who stabilise weight at a moderate deficit tend to report less of it. For context on how individual responses to Mounjaro vary more broadly, the page on whether everyone loses weight on Mounjaro covers response variability in detail.
Thyroid function is worth mentioning separately. Hypothyroidism can independently cause diffuse hair thinning and is occasionally diagnosed in people who assumed shedding was treatment-related. If shedding is severe or persists beyond nine months, it is worth ruling out with a blood test.
Most people who notice shedding see it start between eight and sixteen weeks after a significant increase in weight-loss rate, peak over a few weeks, then gradually slow. By the time weight loss stabilises (or the dose settles at the highest tolerated level) shedding typically subsides. Full density usually returns within a few months of the shedding peak. The pen you kept in the fridge last winter is unlikely to be doing anything harmful to your follicles right now; the body takes time to signal and respond.
Practical steps that are widely recommended by clinicians in this context: aim for at least 1.2–1.6 g of protein per kilogram of body weight daily (your prescriber can give a target suited to you); prioritise iron-rich foods or discuss supplementation if your levels are borderline; check ferritin specifically rather than relying on haemoglobin alone. Biotin supplements are sometimes suggested, though evidence for them in non-deficient people is limited.
It is also worth knowing that stopping Mounjaro is rarely the answer. Shedding continues until the telogen-phase hairs that entered rest have shed, stopping the medicine mid-cycle does not accelerate recovery, and may mean restarting from a lower dose. If you are wondering whether you will lose hair on Mounjaro before committing to treatment, that page sets out what the evidence currently suggests. For anyone weighing up treatment costs alongside benefits, the cost context page covers what to look for in a private prescription service.
If shedding is severe, patchy, or continues beyond nine months without improvement, that warrants a GP appointment to rule out other causes. Our support team can also help connect you with our prescribers if you have concerns mid-treatment.
Telogen effluvium is self-limiting in the vast majority of cases, but there are situations where shedding on Mounjaro deserves a proper clinical look rather than reassurance alone.
Seek advice if: loss is patchy rather than diffuse (patches may suggest alopecia areata, an autoimmune condition unrelated to the medicine); shedding started well beyond the expected 2–4 month window with no obvious pattern; there are other new symptoms such as fatigue, cold intolerance, or changes in skin texture (thyroid markers worth checking); or if density has not begun recovering after nine months of stable dosing.
The NHS page on tirzepatide covers side effects and when to contact a doctor or pharmacist, and is a reliable first reference for any symptom you are unsure about. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is where patients can report any suspected side effect (including hair-related ones) and doing so helps regulators build a fuller picture over time.
Our prescribers review every repeat order before it is dispensed; that is a natural point to raise any symptom that has been bothering you. If you have not yet started treatment and want to understand whether Mounjaro works for everyone before deciding if it suits your situation, that page covers the range of individual outcomes in detail. If you are already mid-treatment and want a thorough look at whether Mounjaro makes you lose hair, that page brings together the clinical picture alongside practical guidance. If you have not yet started treatment and want to discuss whether Mounjaro suits your situation, checking your eligibility through a free consultation is the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.